Citations

Clear

88 citation(s) found for "Beer, K".

Balancing blood pressure and catecholamine support is critical in heart failure-related cardiogenic shock patients
Beer, Benedikt N. , Kellner, Caroline , Sundermeyer, Jonas , Besch, Lisa, Dettling, Angela , Kriz, Marvin , Kirchhof, Paulus , Blankenberg, S, MORICI, Nuccia, Proudfoot, Alastair, Schwinger, Robert H. G., Pauschinger, Matthias , Skurk, Carsten, Jung, Christian, Thiele, Holger, Skurk, Carsten , Jung, Christian , Blankenberg, Stefan , Scherer, Clemens , Mangner, Norman , Proudfoot, Alastair G , Graf, Tobias , Jung, Christian , Thiele, Holger , Schrage, Benedikt , Kirchhof, Paulus , Blankenberg, Stefan , Bertoldi, Letizia Fausta , Lüsebrink, Enzo , Scherer, Clemens , Morici, Nuccia , Proudfoot, Alastair , Schwinger, Robert H. G., Kanwar, Manreet , Jentzer, Jacob C. , Thiele, Hölger , Schrage, Benedikt

Mayo Clinic

European Journal of Heart Failure | January 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ejhf/xuag009 | PMID 41771117 Get It

Abstract Aims Cardiogenic shock (CS) is often treated with catecholamines titrated to an adequate target mean arterial pressure (MAP) while minimizing adverse effects. We aim to assess the optimal catecholamine dose/MAP balance in heart failure-associated CS (HF-CS). Methods Patients with HF-CS were retrospectively enrolled from 16 tertiary centres in 5 European countries (2016–2021; NCT03313687). Dosage was quantified by inotropic scores (epinephrine, norepinephrine, and dobutamine). Associations of baseline and seven-day summarized dosage with intensive care unit (ICU) discharge (mixed-effects logistic regression) and 30-day mortality (Cox regression) were analysed. Potential catecholamine/MAP target ratios for optimized outcomes were assessed in models adjusted for age, sex, pH, lactate and prior resuscitation, stratified by centre. Results N = 704 patients: median age 63 years, 74% male, 34% post-resuscitation, median lactate 5.2 mmol/l. Of these, 53% were discharged from ICU, 48% died within 30 days. Higher inotropic scores independently predicted a lower probability of ICU discharge (baseline score: OR 0.78 [95%-CI 0.69–0.88]; summarized score: OR 0.46 [0.38–0.56]; both P < .001) and higher risk of 30-day mortality (baseline score: HR 1.27 [1.15–1.40], summarized score HR 1.83 [1.60–2.09]; both P < .001). A score/MAP ratio <0.403 µg/kg/min/mmHg was associated with higher ICU discharge odds (ceiling effect); a < 0.426 µg/kg/min/mmHg with lower 30-day mortality hazards (no ceiling effect). Lowering catecholamine doses by accepting reduced MAP targets was linked to better outcomes. Conclusion In HF-CS, higher catecholamine support independently associates with worse outcomes. Accepting lower blood pressure targets to reduce catecholamine dosage may improve outcomes. Validation in randomized controlled trials is urgently needed.
Role of Blood–Brain Barrier Permeability in Delirium Pathophysiology and Treatment
Gruenbaum, Benjamin F. , Dubilеt, Michael , Negev, Shahar, Zeldetz, Vladimir, Merchant, Kiran S. , Boyko, Matthew , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Zlotnik, Alexander Anatolievich

Mayo Clinic

Anesthesiology | December 9, 2025 | Volume: 144 | Issue: 1 | Pages: 203-229

10.1097/aln.0000000000005722 | PMID 41363873 Get It

Delirium is a serious neuropsychiatric condition marked by acute confusion and cognitive decline, commonly affecting postoperative and critically ill patients. It is especially prevalent in older adults and those requiring intensive care, including patients undergoing major surgery or receiving mechanical ventilation. For anesthesiologists, delirium is a critical and often underrecognized postoperative complication with complex perioperative contributors. Intensive care unit patients with delirium face increased mortality, cognitive impairment, and persistent symptoms beyond discharge. Despite its clinical significance, the pathophysiology of delirium remains poorly understood, with no standardized classification or targeted therapy. In light of emerging evidence connecting blood–brain barrier (BBB) permeability to the onset of delirium, we found that BBB dysfunction may represent a key mechanism underlying its pathophysiology. Through a thorough examination of predisposing and precipitating factors that impair both BBB integrity and cognitive function, we identified many points of connection between BBB dysfunction and delirium specifically. We include here a summary of our diagnostic approach with the aim of improving therapeutic strategies based on preserving BBB function to prevent or mitigate delirium.
Abstract PR005: Exploiting CTPS1 dependency for the treatment of ovarian cancer
Wang, Xiyin , Emch, Michael J. , Voll, Lauren, Epp, Rebecca, Rodman, Esther , Odell, Noa, Pearson, Nicole A, Hou, Xiaonan , Goetz, Matthew P. , Weroha, S. John, Hawse, John R. , Epp, Rebecca, Odell, Noa, Goetz, Matthew P. , Kaufmann, Scott H. , Weroha, S. John, Beer, Philip

Mayo Clinic

Cancer Research | September 19, 2025 | Volume: 85 | Issue: 18_Supplement | Pages: PR005-PR005

10.1158/1538-7445.ovarian25-pr005 Get It

Abstract Despite therapeutic advances, ovarian cancer (OC) recurrence remains common and outcomes for advanced disease are poor, highlighting the need for novel therapeutic targets. To this end, we identified CTPS1 as a highly expressed and essential gene for the survival of many OC cell lines, including models resistant to chemotherapy and PARP inhibitors. CTPS1 is one of two enzymes, alongside CTPS2, responsible for the de novo synthesis of cytidine triphosphate (CTP), a critical nucleotide required for DNA and phospholipid biosynthesis. We discovered that CTPS1 is the predominant isoform expressed in OC cells, with significantly higher levels of expression in advanced and resistant disease compared to normal tissue, benign lesions and treatment naïve cancers. Intriguingly, 25% of all OC samples were found to completely lack CTPS2 protein expression suggesting their near complete reliance on CTPS1 for survival. Using CTPS1 siRNAs and genetically engineered OC cells with a degradation tag (dTAG) fused to the C-terminus of endogenous CTPS1 alleles, we showed that CTPS1 knockdown or proteasomal degradation induces an S-phase cell cycle arrest followed by apoptosis. Leveraging a first-in-class, highly selective, and orally bioavailable CTPS1 inhibitor (STP938) developed by Step Pharma, we identified nanomolar-range IC50 values across a panel of over 20 OC cell lines and validated its anti-neoplastic activity in ex vivo patient-derived xenograft (PDX) models. STP938 synergized with standard-of-care chemotherapy and PARP inhibitors, even in resistant models, further supporting its clinical potential. To elucidate STP938’s mechanism of action, we performed multi-omic profiling (bulk RNAseq, phospho- and total proteomics) on sensitive and isogenic resistant OC lines, as well as single-cell RNAseq of an OC PDX tumor following in vivo treatment with vehicle or STP938, revealed dysregulation of DNA replication, cell cycle, and metabolic pathways. As expected, STP938 rapidly depleted CTP levels, which remain suppressed for 72 hours, suggesting insufficient salvage pathway compensation which ultimately compromised cancer cell viability. As CTP is also a direct precursor for activated intermediates in phospholipid biosynthesis. Mass-spectrometry based lipidomics and metabolomics were employed to interrogate the impact of STP938 in these processes where numerous changes were found. To uncover mechanisms of resistance to STP938 and reveal therapeutic vulnerabilities, we conducted genome-wide CRISPR knockout screens in multiple treatment naïve and STP938 resistant models and analysis of results are ongoing. In collaboration with Step Pharma, a Phase 1a/b clinical trial of STP938 is currently enrolling patients with advanced solid tumors, including an expansion cohort for CTPS2 null OC patients (NCT06297525). These laboratory discoveries and ongoing clinical efforts aim to enable broader uptake of this novel therapeutic approach to improve long-term outcomes in patients with CTPS1-dependent disease. Citation Format: Xiyin Wang, Michael J. Emch, Lauren A. Voll, Rebecca Epp, Esther P. Rodman, Noa Odell, Nicole A. Pearson, Xiaonan Hou, Matthew P. Goetz, Scott H. Kaufmann, S. John Weroha, Philip Beer, John R. Hawse. Exploiting CTPS1 dependency for the treatment of ovarian cancerPR005: Exploiting CTPS1 dependency for the treatment of ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr PR005.
Modifying inhibitor specificity for homologous enzymes by machine learning
Gozlan, Dor S. , Meiri, Reut , Shapira, Gili, Radisky, Evette S. , Orenstein, Yaron , Papo, Niv , Coban, Matt , Radisky, Evette S , Orenstein, Yaron , Papo, Niv , Shapira, Gili

Mayo Clinic

The FEBS Journal | September 6, 2025 | Volume: 293 | Issue: 4 | Pages: 1007-1023

10.1111/febs.70249 | PMID 40912922 Get It

Selective inhibitors are essential for targeted therapeutics and for probing enzyme functions in various biological systems. The two main challenges in identifying such protein‐based inhibitors lie in the extensive experimental effort required, including the generation of large libraries, and in tailoring the selectivity of inhibitors to enzymes with homologous structures. To address these challenges, machine learning (ML) is being used to improve protein design by training on targeted libraries and identifying key interface mutations that enhance affinity and specificity. However, such ML‐based methods are limited by inaccurate energy calculations and difficulties in predicting the structural impacts of multiple mutations. Here, we present an ML‐based method that leverages HTS data to streamline the design of selective protease inhibitors. To demonstrate its utility, we applied our new method to find inhibitors of matrix metalloproteinases (MMPs), a family of homologous proteases involved in both physiological and pathological processes. By training ML models on binding data for three MMPs (MMP‐1, MMP‐3, and MMP‐9), we successfully designed a novel N‐TIMP2 variant with a differential specificity profile, namely, high affinity for MMP‐9, moderate affinity for MMP‐3, and low affinity for MMP‐1. Our experimental validation showed that this novel variant exhibited a significant specificity shift and enhanced selectivity compared with wild‐type N‐TIMP2. Through molecular modeling and energy minimization, we obtained structural insights into the variant's enhanced selectivity. Our findings highlight the power of ML‐based methods to reduce experimental workloads, facilitate the rational design of selective inhibitors, and advance the understanding of specific inhibitor–enzyme interactions in homologous enzyme systems.
Sensitivity of Diffusion Tensor Imaging for Assessing Injury Severity in a Rat Model of Isolated Diffuse Axonal Injury: Comparison with Histology and Neurological Assessment
Zvenigorodsky, Vladislav , Gruenbaum, Benjamin F. , Shelef, Ilan , Frank, Dmitry , Tsafarov, Beatris, Negev, Shahar, Zeldetz, Vladimir, Azab, Abed N., Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Boyko, Matthew , Shelef, Ilan , Zlotnik, Alexander Anatolievich

Mayo Clinic

International Journal of Molecular Sciences | July 29, 2025 | Volume: 26 | Issue: 15 | Pages: 7333

10.3390/ijms26157333 | PMID 40806467 Get It

Diffuse axonal brain injury (DAI) is a common, debilitating consequence of traumatic brain injury, yet its detection and severity grading remain challenging in clinical and experimental settings. This study evaluated the sensitivity of diffusion tensor imaging (DTI), histology, and neurological severity scoring (NSS) in assessing injury severity in a rat model of isolated DAI. A rotational injury model induced mild, moderate, or severe DAI in male and female rats. Neurological deficits were assessed 48 h after injury via NSS. Magnetic resonance imaging, including DTI metrics, such as fractional anisotropy (FA), relative anisotropy (RA), axial diffusivity (AD), mean diffusivity (MD), and radial diffusivity (RD), was performed prior to tissue collection. Histological analysis used beta amyloid precursor protein immunohistochemistry. Sensitivity and variability of each method were compared across brain regions and the whole brain. Histology was the most sensitive method, requiring very small groups to detect differences. Anisotropy-based MRI metrics, especially whole-brain FA and RA, showed strong correlations with histology and NSS and demonstrated high sensitivity with low variability. NSS identified injury but required larger group sizes. Diffusivity-based MRI metrics, particularly RD, were less sensitive and more variable. Whole-brain FA and RA were the most sensitive MRI measures of DAI severity and were comparable to histology in moderate and severe groups. These findings support combining NSS and anisotropy-based DTI for non-terminal DAI assessment in preclinical studies.
Recent-onset atrial fibrillation: challenges and opportunities
Svennberg, Emma , Andrade, Jason G. , Anselmino, Matteo , Biton, Yitschak , Brandes, Axel , Buckley, Claire , Espuny, Josep Lluis Clua , Doehner, Wolfram , Domínguez, Helena , Fauchier, Laurent , Glotzer, Taya V. , Hendriks, Jeroen , Hills, Mellanie True , Hindricks, Gerhard , Joung, Boyoung , Levin, Lars‐Åke , Liu, Shaowen , Lobban, Trudie , Macfarlane, Peter W. , Mairesse, Georges H. , Marcus, Gregory M. , Orchard, J. , Reiffel, James A. , Siontis, Konstantinos C. , Stavrakis, Stavros , Svendsen, Jesper Hastrup , Teh, A. , Tieleman, Robert G , Camm, A. John , Freedman, Ben , Andrade, Jason G , Anselmino, Matteo , Biton, Yitschak , Boriani, Giuseppe , Brandes, Axel , Buckley, Claire , Cameron, Alan C , Lluis Clua Espuny, Josep , Crijns, Harry J G M , Diederichsen, Søren Z , Doehner, Wolfram , Dominguez, Helena , Duncker, David , Fauchier, Laurent , Glotzer, Taya , Guo, Yutao , Haeusler, Karl G , Haim, Moti , Healey, Jeffrey S , Hendriks, Jeroen M , True Hills, Mellanie , Hindricks, Gerhard , Hobbs, F D Richard , Johnson, Linda S B , Joung, Boyoung , Kamel, Hooman , Kirchhof, Paulus , Lane, Deirdre A , Levin, Lars-Åke , Lip, Gregory Y H , Liu, Shaowen , Lobban, Trudie , Macfarlane, Peter W , Mairesse, Georges , Marcus, Gregory M , Noseworthy, Peter A , Ntaios, George , Orchard, Jessica J , Passman, Rod , Reidpath, Daniel D , Reiffel, James A , Ribeiro, Antonio Luiz , Rivard, Lena , Sanders, Prashanthan , Sandhu, Roopinder K , Schnabel, Renate B , Siontis, Konstantinos C , Sposato, Luciano A , Stavrakis, Stavros , Steinhubl, Steven , Svendsen, Jesper Hastrup , Teh, Andrew W , Themistoclakis, Sakis , Tieleman, Robert G , Camm, Alan John , Freedman, Ben , Boriani, Giuseppe , Cameron, Alan C. , Crijns, Harry J.G.M. , Diederichsen, Søren Zöga , Duncker, David , Haim, Moti , Healey, Jeff S. , Hobbs, Richard , Johnson, Linda S.B. , Kamel, Hooman , Kirchhof, Paulus , Lane, Deirdre A. , Noseworthy, Peter A. , Passman, Rod , Rivard, Léna , Sanders, Prashanthan , Schnabel, Renate B. , Sposato, Luciano A. , Tieleman, RG

Mayo Clinic

European Heart Journal | June 23, 2025 | Volume: 47 | Issue: 2 | Pages: 170-187

10.1093/eurheartj/ehaf478 | PMID 40873195 Get It

Abstract Atrial fibrillation (AF) is increasingly diagnosed early, close to its first occurrence due to: (i) increased public awareness with self-screening; (ii) health care initiatives including population screening and opportunistic case finding; and (iii) increased use and surveillance of implantable cardiac devices. At its onset, AF is often low burden, and cardiovascular co-morbidities may be absent or at an early stage. Thus, the management of recent-onset AF has become an issue of growing importance. Professional guidelines have traditionally focused on anticoagulant thromboprophylaxis, generally recommending a cautious approach to rhythm control, and priority has been given to rate control to alleviate symptoms. In recent guidelines, the importance of managing lifestyle and co-morbidities has increased. The AF-SCREEN collaboration proposes that a vigorous approach to active management of recent-onset AF may be warranted. This includes addressing co-morbidities and promoting healthy lifestyles to prevent the emergence or progression of AF and associated cardiovascular disease, as well as the initiation of active rhythm control ± anticoagulation to prevent AF-related morbidity and mortality, including stroke and heart failure (HF). Intuitively, intervention early after AF onset would be beneficial since lifestyle and co-morbidity management, plus rhythm control and anticoagulation, are important contributors to improved outcomes in patients with established AF, but robust evidence is lacking for recent-onset AF. There is a delicate balance between achieving favourable outcomes such as preventing strokes, HF and AF progression vs the complications and potential adverse effects of interventions. Given the serious long-term consequences, innovative approaches are necessary to determine the value and risks of initiating active therapy very early in the course of AF. More data are needed to guide the best management of recent-onset AF, bearing AF burden in mind. Long-term studies using large national databases linked to electronic medical records and rhythm monitoring devices offer excellent opportunities. Shorter-term studies focusing on reducing AF burden to slow AF progression and studies focusing on outcomes such as HF could be used in both randomized clinical trials and observational cohort studies.